MDxHealth (NASDAQ:MDXH) Rating Lowered to Hold at Craig Hallum

MDxHealth (NASDAQ:MDXH) was downgraded by equities research analysts at Craig Hallum from a “buy” rating to a “hold” rating in a research report issued on Friday, MarketBeat reports.

A number of other equities analysts also recently issued reports on MDXH. Lake Street Capital set a $3.00 price target on MDxHealth and gave the stock a “buy” rating in a research report on Friday, August 14th. Weiss Ratings lowered shares of MDxHealth from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 8th. BTIG Research lowered their price objective on shares of MDxHealth from $4.00 to $2.00 and set a “buy” rating for the company in a research note on Friday, August 21st. Finally, Wall Street Zen upgraded shares of MDxHealth to a “sell” rating in a report on Saturday, August 15th. Two equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $1.33.

MDxHealth Price Performance

Shares of NASDAQ MDXH opened at $0.60 on Friday. MDxHealth has a 1 year low of $0.40 and a 1 year high of $5.33. The firm has a 50-day simple moving average of $0.65 and a two-hundred day simple moving average of $0.93. The company has a market cap of $29.88 million, a P/E ratio of -0.84 and a beta of 1.68.

MDxHealth (NASDAQ:MDXH) last released its earnings results on Friday, August 14th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01. The business had revenue of $27.21 million for the quarter, compared to the consensus estimate of $26.14 million. As a group, equities research analysts expect that MDxHealth will post -0.49 EPS for the current year.

Institutional Trading of MDxHealth

A number of institutional investors have recently modified their holdings of the company. Squarepoint Ops LLC acquired a new stake in MDxHealth in the second quarter valued at approximately $82,000. Bank of America Corp DE raised its holdings in shares of MDxHealth by 213.9% in the first quarter. Bank of America Corp DE now owns 43,492 shares of the company’s stock worth $100,000 after buying an additional 29,638 shares during the last quarter. Renaissance Technologies LLC raised its stake in MDxHealth by 21.8% in the 1st quarter. Renaissance Technologies LLC now owns 304,700 shares of the company’s stock worth $701,000 after acquiring an additional 54,600 shares during the last quarter. Finally, Perkins Capital Management Inc. boosted its position in MDxHealth by 7.1% in the first quarter. Perkins Capital Management Inc. now owns 1,476,441 shares of the company’s stock valued at $3,396,000 after buying an additional 97,500 shares during the last quarter.

MDxHealth Company Profile

MDxHealth is a precision diagnostics company focused on improving the detection, diagnosis and management of cancer. The company develops and commercializes molecular and genomic tests designed to help physicians assess cancer risk, guide treatment decisions and monitor patients, with a primary focus on urological cancers.

Its product portfolio includes ConfirmMDx, a tissue-based test intended to help identify men who may have clinically significant prostate cancer after a prior negative biopsy; SelectMDx, a urine-based test that helps assess the likelihood of clinically significant prostate cancer; and ResolveMDx, a molecular test designed to support prostate cancer risk assessment.